Genetic and gene expression studies, in humans and animal models of psychiatric and
other medical disorders, are becoming increasingly integrated. Particularly for genomics, the …

We have initiated and developed over the last decade a translational methodology,
convergent functional genomics (CFG), that integrates in a Bayesian fashion multiple lines of …

Genome-wide association studies and other discovery genetics methods provide a means to
identify previously unknown biological mechanisms underlying behavioral disorders that …

Identifying genes involved in complex neuropsychiatric disorders through classic human
genetic approaches has proven difficult. To overcome that barrier, we have developed a …

The past decade has been one of unprecedented discovery in psychiatry. Large-scale
genomic studies have identified hundreds of molecular risk factors and illuminated the …

Most neuropsychiatric disorders are highly polygenic, implicating hundreds to thousands of
causal genetic variants that span much of the genome. This widespread polygenicity …

The primary aim of precision medicine is to tailor healthcare more closely to the needs of
individual patients. This requires progress in two areas: the development of more precise …

The possibility of establishing a metric of individual genetic risk for a particular disease or
trait has sparked the interest of the clinical and research communities, with many groups …

Recent large-scale genetic approaches such as genome-wide association studies have
allowed the identification of common genetic variations that contribute to risk architectures of …

The Psychiatric Genomics Consortium (PGC) is the largest consortium in the history of
psychiatry. This global effort is dedicated to rapid progress and open science, and in the …